Answers are grounded in this paper and cite their sources.
Ovarian cancer usually responds well to chemotherapy, but once the disease becomes resistant to chemotherapy, the treatment options available are inadequate. A number of strategies are currently undergoing clinical evaluation, among which angiogenesis and PARP [poly(ADP-ribose) polymerase] inhibitors appear promising. Pre-clinical studies have identified several potential new therapeutic strategies, and we review the potential for use of BH3 (Bcl-2 homology) mimetics, autotaxin inhibitors and statins to treat ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Fisher et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: